Study S002644

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 52-Week Trial to Investigate the Efficacy and Safety of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07830329
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 300
Start: 2026-10-30
Primary completion: 2028-11-24
Lead sponsor: Regeneron Pharmaceuticals
Conditions: Hidradenitis Suppurativa
Interventions: DRUG:Olatorepatide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: CTIS:2026-526375-39-00

Registered primary outcomes

Percent change in total Abscess and inflammatory Nodule (AN) count [From baseline to week 52]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.